Publication:
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3)

Simple item page
dc.contributor.authorAllemani, Claudia
dc.contributor.authorMatsuda, Tomohiro
dc.contributor.authorDi Carlo, Veronica
dc.contributor.authorHarewood, Rhea
dc.contributor.authorMatz, Melissa
dc.contributor.authorNikšić, Maja
dc.contributor.authorBonaventure, Audrey
dc.contributor.authorValkov, Mikhail
dc.contributor.authorJohnson, Christopher J
dc.contributor.authorEstève, Jacques
dc.contributor.authorOgunbiyi, Olufemi J
dc.contributor.authorChen, Wan-Qing
dc.contributor.authorEser, Sultan
dc.contributor.authorEngholm, Gerda
dc.contributor.authorStiller, Charles
dc.contributor.authorMonnereau, Alain
dc.contributor.authorWoods, Ryan
dc.contributor.authorVisser, Otto
dc.contributor.authorHsiang Lim, Gek
dc.contributor.authorAitken, Joanne
dc.contributor.authorWeir, Hannah K
dc.contributor.authorColeman Michel P.
dc.contributor.authorCONCORD Working Group
dc.date.accessioned2023-06-06T17:59:14Z
dc.date.available2023-06-06T17:59:14Z
dc.date.issued2019-03
dc.description.abstractBackground—In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival, as a metric of the effectiveness of health systems and to inform global policy on cancer control. Methods—CONCORD-3 updates the world-wide surveillance of cancer survival to 2014, with individual data for 37.5 million patients diagnosed with cancer during the 15-year period 2000–2014. Data were provided by 322 population-based cancer registries in 71 countries and territories, of which 47 provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate and melanoma of the skin in adults, and brain tumours, leukaemias and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated five-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights. Findings—For most cancers, five-year net survival remains among the highest in the world in the US and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas and lung. For women diagnosed during 2010–2014, the predicted five-year survival for breast cancer is now close to 90% in the US and in Australia, but international differences remain very wide, with levels as low as 40% in South Africa. For gastrointestinal cancers, the highest levels of five-year survival are seen in South-East Asia, in Korea for cancers of the stomach (69%), colon (72%) and rectum (71%), in Japan for oesophageal cancer (36%) and in Taiwan for liver cancer (28%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (60% in Korea, 52% in Taiwan, 50% in China), and for both lymphoid malignancies (53% in Korea, 51% in Taiwan, 38% in China) and myeloid malignancies (46% in Korea, 33% in Taiwan, 25% in China). For children diagnosed during 2010–2014, five-year survival for acute lymphoblastic leukaemia ranged from 66% in Thailand to 95% in Finland. Five-year survival from brain tumours in children is higher than for adults, and the global range is very wide (from 45% in Thailand to 80% in Sweden and Denmark). Interpretation—The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed world-wide every year. It contributes to the evidence base for global policy on cancer control. From 2017, the Organisation for Economic Co-operation and Development will use findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries world-wide. It is crucial for governments to recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer
dc.identifier.citationAllemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Azevedo E Silva G, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP; CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018 Mar 17;391(10125):1023-1075. doi: 10.1016/S0140-6736(17)33326-3. Epub 2018 Jan 31. PMID: 29395269; PMCID: PMC5879496.
dc.identifier.urihttp://biblioteca.solcaquito.org.ec:9997/handle/123456789/243
dc.language.isoen
dc.publisherThe Lancet
dc.titleGlobal surveillance of trends in cancer survival 2000-14 (CONCORD-3)
dc.typeArticle
dspace.entity.typePublication
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3).pdf
Size:
1.67 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
Artículos científicos
PubMed